Payment overview · 2025
General Payments
$4,117.10
194 reported records · 20 companies
Healthcare provider profile · identity verified
Robert A Houghton, M.D.
Allopathic & Osteopathic Physicians|General Practice · SAN DIEGO, CA · NPI 1124138045
Verified facts
What the public records show
CMS Open Payments records show Robert A Houghton, M.D. received $4,117.10 in general payments during 2025 across 194 reported records.
Gilead Sciences, Inc. accounted for 40.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Biktarvy, Dovato, Farxiga, Ozempic, Pifeltro, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Farxiga by this doctor in 2024.
EMD Serono, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Serostim as an associated drug or biological on 153 records involving 74 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Serostim by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Biktarvy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Descovy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Trelegy Ellipta by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PIFELTRO as an associated drug or biological on 7921 records involving 2912 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Pifeltro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Eliquis by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Dovato by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $1,679.45 | 40.8% | 96 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $1,315.83 | 32.0% | 47 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $340.38 | 8.3% | 13 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $163.32 | 4.0% | 11 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $90.62 | 2.2% | 5 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $84.25 | 2.0% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $68.89 | 1.7% | 3 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $61.23 | 1.5% | 3 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $55.15 | 1.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $45.61 | 1.1% | 2 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $30.35 | 0.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $26.65 | 0.7% | 1 | 2025 |
| Theratechnologies Inc. | Unresolved — no canonical attribution shown | $25.25 | 0.6% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $22.73 | 0.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $21.71 | 0.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.95 | 0.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.05 | 0.5% | 1 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.97 | 0.4% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.62 | 0.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.09 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,117.10 | 194 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $732.83 | 27 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $404.35 | 11 | 2025 |
Source payment records
|
|||||
| Yeztugo Normalized: yeztugo |
Drug | Gilead Sciences, Inc. | $243.66 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $239.39 | 8 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $116.27 | 2 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $112.30 | 6 | 2025 |
Source payment records
|
|||||
| Biktarvy Normalized: biktarvy |
Drug | Gilead Sciences, Inc. | $106.92 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $106.77 | 8 | 2025 |
Source payment records
|
|||||
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $84.25 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $75.13 | 4 | 2025 |
Source payment records
|
|||||
| RUKOBIA Normalized: rukobia |
Drug | ViiV Healthcare Company | $66.35 | 3 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $61.23 | 3 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $55.15 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $45.61 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $45.61 | 2 | 2025 |
Source payment records
|
|||||
| MENQUADFI Normalized: menquadfi |
Biological | SANOFI PASTEUR INC. | $44.21 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $38.64 | 2 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $35.00 | 2 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $35.00 | 2 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $35.00 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $33.81 | 1 | 2025 |
Source payment records
|
|||||
| TERIPARATIDE Normalized: teriparatide |
Drug | Almatica Pharma LLC | $30.35 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $30.25 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $30.25 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $26.65 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $26.65 | 1 | 2025 |
Source payment records
|
|||||
| EGRIFTA Normalized: egrifta |
Drug | Theratechnologies Inc. | $25.25 | 1 | 2025 |
Source payment records
|
|||||
| TROGARZO Normalized: trogarzo |
Drug | Theratechnologies Inc. | $25.25 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $24.12 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $22.73 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $21.71 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $21.55 | 1 | 2025 |
Source payment records
|
|||||
| DELSTRIGO Normalized: delstrigo |
Drug | Merck Sharp & Dohme LLC | $20.39 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $19.95 | 1 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $19.05 | 1 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $15.97 | 1 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $15.62 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Biktarvy biktarvy |
2025 | Biktarvy | 2024 | 75 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| DOVATO dovato |
2025 | Dovato | 2024 | 121 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PIFELTRO pifeltro |
2025 | Pifeltro | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| EMD Serono, Inc. Exact reporting entity; no affiliate inference |
2025 | Serostim open payments reported associated product |
CMS Open Payments — General Payments 153 supporting records · 74 recipient NPIs · example record 1236871463 |
Serostim · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
75 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | PIFELTRO open payments reported associated product |
CMS Open Payments — General Payments 7921 supporting records · 2912 recipient NPIs · example record 1237992198 |
Pifeltro · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
121 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 211 | 51 |
| Metformin Hcl | Metformin Hcl | 132 | 37 |
| Dovato | Dolutegravir Sodium/Lamivudine | 121 | 12 |
| Losartan Potassium | Losartan Potassium | 120 | 29 |
| Amlodipine Besylate | Amlodipine Besylate | 90 | 20 |
| Trazodone Hcl | Trazodone Hcl | 89 | 16 |
| Lisinopril | Lisinopril | 88 | 25 |
| Alendronate Sodium | Alendronate Sodium | 84 | 17 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 75 | suppressed |
| Omeprazole | Omeprazole | 64 | 17 |
| Testosterone | Testosterone | 63 | 14 |
| Acyclovir | Acyclovir | 62 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 52 | 15 |
| Gabapentin | Gabapentin | 50 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 46 | 12 |
| Sertraline Hcl | Sertraline Hcl | 44 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 43 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 12 |
| Farxiga | Dapagliflozin Propanediol | 42 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 41 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 41 | 11 |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 40 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 39 | suppressed |
| Anastrozole | Anastrozole | 37 | suppressed |
| Atenolol | Atenolol | 36 | 11 |
| Metoprolol Succinate | Metoprolol Succinate | 36 | suppressed |
| Prezcobix | Darunavir/Cobicistat | 36 | suppressed |
| Alprazolam | Alprazolam | 33 | 11 |
| Pantoprazole Sodium | Pantoprazole Sodium | 33 | suppressed |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Temazepam | Temazepam | 30 | suppressed |
| Carvedilol | Carvedilol | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 25 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | suppressed |
| Famotidine | Famotidine | 24 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 23 | suppressed |
| Valganciclovir Hcl | Valganciclovir Hcl | 23 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 22 | suppressed |
| Pifeltro | Doravirine | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Jardiance | Empagliflozin | 21 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 13 |
| Finasteride | Finasteride | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 12 |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 16 | suppressed |
| Allopurinol | Allopurinol | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 14 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 14 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Eliquis | Apixaban | 13 | suppressed |
| Lamivudine Hbv | Lamivudine | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Simvastatin | Simvastatin | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | 11 |
| Serostim | Somatropin | 12 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Fluocinonide | Fluocinonide | 11 | suppressed |
| Ozempic | Semaglutide | 11 | suppressed |
| Potassium Chloride | Potassium Chloride | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,117.10 · 194 records | Gilead Sciences, Inc. | AIRSUPRA, APRETUDE, AREXVY, AVEIR, AVYCAZ, BEYFORTUS, BREZTRI, Biktarvy, CABENUVA, CAPVAXIVE, Cologuard Collection Kit, DALVANCE, DELSTRIGO, DOVATO, EDARBI, EGRIFTA, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, Flucelvax, INSPIRE, LEQVIO, MAVYRET, MENQUADFI, NURTEC ODT, Ozempic, PIFELTRO, REPATHA, RUKOBIA, Rybelsus, SHINGRIX, TEFLARO, TERIPARATIDE, TRELEGY ELLIPTA, TROGARZO, Tlando, VRAYLAR, Yeztugo, ZAVZPRET | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Biktarvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error